artificial tears

Biologic products increase dry eye optionsMany new diagnostic tools are available for dry eye and ocular surface disease (OSD). Treatments for dry eye and OSD have mixed results, however, said Bennie H. Jeng, MD.
Surveying the artificial tear landscapePatients use artificial tears for different reasons and diverse conditions. While available products supplement tear production and provide relief, few distinctions between drops have been clearly established. Recent studies show that direct comparison of a new product to an older, established one and use of “real-world” metrics can be most useful to prescribers.
The evolution of tear substitutesIn an ongoing effort to ameliorate the discomfort and blurred vision that stems from dry eye, tear substitutes have undergone numerous improvements to enhance their efficacy and safety to the ocular surface.
Lifitegrast promising for patients using artificial tearsJohn Sheppard, MD, highlights results of a phase III randomized, double-masked, placebo-controlled trial of lifitegrast in dry eye patients previously on artificial tears. He presented these results, a subset analysis of the OPUS-1 phase III trial, at the 2013 meeting of the American Society of Cataract and Refractive Surgery.
Dry eye therapy seeks to fill unmet need in artificial tearsThrough the generations of artificial tears, ophthalmology has seen a number of advanced therapeutic options.